Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Hematology | Internal Medicine | Oncology | Institutional

Back to Journal Articles

NCCN and Proventys Collaborate to Provide Point of Care Access to Guidelines

Last Updated: July 26, 2010.

Fort Washington, Penn. and Newton, Mass., July 26, 2010 – The National Comprehensive Cancer Network® (NCCN®) and Proventys, a leader in advanced decision support technologies, have entered into an exclusive collaboration to introduce the Proventys CDS Oncology™ system, a first-of-its-kind Web platform that arms oncologists with expert recommendations and evidence facilitating the delivery of high-quality individualized patient care. Through this collaboration, Proventys and NCCN are bringing together the recognized standard in oncology clinical guidelines and novel informatics technologies to help clinicians optimize treatment decisions for patients while improving practice efficiencies. 

In today’s complex healthcare environment, clinicians are facing increasing pressure to provide high-quality, cost-effective care consistent with evidence-based standards of medical practice. To address this demand, Proventys CDS Oncology was designed to automate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) in a dynamic and structured fashion according to individual patient characteristics, and enable clinicians to access evidence-based recommendations efficiently within the clinical workflow. The Proventys system offers clinicians guidance on appropriate lab and imaging tests, provides information on cancer staging and highlights the most relevant treatment regimens available for the patient based on NCCN Guidelines and other decision rules. As a key component of the collaboration, Proventys CDS Oncology will also feature real-time alerts of critical updates to the NCCN Guidelines reflecting the latest recommendations for cancer therapy. 

“For clinicians to deliver the highest standard of care to cancer patients, it’s imperative that they have easy, quick access to critical information that helps guide them in their treatment decisions,” said William T. McGivney, Ph.D., Chief Executive Officer of NCCN. “This collaboration with Proventys gives us the opportunity to equip clinicians with point-of-care access to the NCCN Guidelines and an ability to incorporate patient-specific factors through novel technology that assists clinical decision-making.”

“The collaboration between Proventys and NCCN represents the perfect blend of evidence-based medicine and information technology,” said Surya Singh, M.D., Chief Medical Officer and Vice President of Clinical Development for Proventys. “Through our innovative informatics approach and NCCN’s gold standard in oncology guidelines, we are, in essence, enhancing clinicians’ ability to process complex data and treat their patients in a more personalized manner.”

Proventys CDS Oncology will be available for clinicians starting in Q4 2010 and will also be offered through payer-sponsored quality programs. The system will initially include NCCN Guidelines for Breast, Colon, and Non-Small Cell Lung cancers as well as Hodgkin lymphoma.

About Proventys

Proventys is a healthcare technology company developing advanced decision support solutions that help clinicians optimize treatment decisions at the point of care in oncology, cardiology and other areas.  The Company has an exclusive relationship with the National Comprehensive Cancer Network (NCCN) to develop and commercialize the Proventys CDS Oncology™ system, an innovative decision support platform that dynamically renders the NCCN Guidelines and prompts clinicians with recommended treatment options based on individual patient characteristics.  The Company also has developed the Proventys PDx Oncology™ system, a novel medical device that delivers software-based predictive tests targeting specific clinical events.  Its lead predictive test, the FN PDx™, assesses an adult cancer patient’s individualized risk of febrile neutropenia (FN), a serious adverse event of chemotherapy.  The product is under review by the FDA (de novo) and not available for sale in the United States.

Based in Newton, Massachusetts, Proventys is dedicated to aligning the interests of providers and payers by offering solutions that personalize care and improve outcomes.  For more information, visit

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit

Previous: FDA Panels Vote Against Plan to Reduce Opioid Abuse Next: Depression May Compromise Treatment for Hepatitis C Virus

Reader comments on this article are listed below. Review our comments policy.

Submit your opinion: